Anebulo Pharmaceuticals, Inc. — Investor Relations & Filings

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing therapies for substance use disorders, with a primary focus on acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning. The company's lead investigational candidate, ANEB-001, is a potent, small-molecule cannabinoid receptor antagonist designed to rapidly reverse the symptoms of cannabis overdose. Anebulo aims to address the growing unmet medical need for an antidote to ACI, driven by the increasing legalization of cannabis and a corresponding rise in related emergency department visits, particularly among vulnerable populations like children. The development of ANEB-001 targets a rapid and clinically impactful solution for emergency medical settings.